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ABSTRACT 
 
As chemotherapeutic backbone for breast cancer therapy, doxorubicin showed various side 
effects and induced resistancy of breast cancer cells. Development of targeted therapy on breast 
cancer focused on combinatorial therapy of doxorubicin and molecular targeted agents. PGV-0 and 
PGV-1, a curcumin analogue showed potency as co-chemotherapeutic agent with doxorubicin. Our 
previous study of PGV-0 and PGV-1 showed cytotoxic activity in T47D cells. Therefore, the aim of 
this research is to examine the synergistic effect of PGV-0, PGV-1 on the cytotoxic activity of 
doxorubicin through cell cycle modulation and apoptotic induction on MCF-7 breast cancer cell 
lines. The cytotoxic assay of PGV-0, PGV-1, doxorubicin, and their combination were carried out by 
using MTT assay. Cell cycle distribution and apoptosis were determined by flowcytometer FACS-
Calibur and the flowcytometry data was analyzed using Cell Quest program. Single treatment of 
PGV-0, PGV-1 and doxorubicin showed cytotoxic effect on MCF-7 with cell viability IC50 value 50 
µM, 6 µM and 350 nM respectively. Single treatment of Doxorubicin 175 nM induced G2/M arrest. 
Single treatment of PGV-0 5 µM induced G2/M arrest while in higher dose 12.5  µM, PGV-0 
induced apoptosis. Combination of doxorubicin 175 nM and PGV-0 5 µM induced apoptosis. 
Combination of doxorubicin 175 nM and PGV-0 12.5 µM also increased apoptosis induction. Single 
treatment of PGV-1 0.6 µM induced G1 arrest while in higher dose 1.5  µM, PGV-1 induced 
apoptosis. Combination of doxorubicin 175 nM and PGV-1 0.6 µM induced apoptosis. Combination 
of doxorubicin 175 nM and PGV-0 1.5 µM also increased apoptosis induction. PGV-0 and PGV-1 
are potential to be delevoped as co-chemotherapeutic agent for breast cancer by inducing 
apoptosis and cell cycle modulation, but the molecular mechanism need to be explored detail.  
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INTRODUCTION 
Breast cancer is one of most the death-
cause cancer in women in the world (Jemal et 
al., 2007). Doxorubicin is one of chemothe-
rapeutic agent mostly used in breast cancer 
therapy. Using of doxorubicin at high dose 
causes side effect on normal tissue, primarily 
on heart, and suppression of immune system. 
Breast cancer cells also showed resistance to 
chemotherapeutic agent such as doxorubicin. 
To improve the antitumor efficacy of chemo-
therapy, a combination with chemopreventive 
agent (co-chemotherapy) would be interesting 
to evaluate.  
PGV-0 [Pentagamavunon-0 (2,5-bis-(4´-
hydroxy-3´-methoxybenzilidine)-
cyclopentanone)] and PGV-1 [Pentagama-
vunon-1 (2,5-bis-(4 -hydroxi,3 ,5 -dimethyl)-
benzylidin-cylopentanone)], a curcumin 
analogue, shows stronger cytotoxic effect than 
curcumin in several cancer cell lines. Our 
previous study of PGV-0 cytotoxic activity on 
T47D cells with IC50 of 9.4 µM seemingly 
potential to be developed as combinatorial 
agent with doxorubicin. PGV-1 also showed 
cytotoxic activity on T47D cells with IC50 1.8 
µM and represent a new microtubule inhibitor.  
Those researches showed the potency of 
PGV-0 and PGV-1 as chemopreventive agent 
and became a basic for the development of 
PGV-0 and PGV-1 as co-chemotherapeutic 
agent to increase the cytotoxic activity and 
reduce the side effects of doxorubicin. 
Therefore, the purpose of this research is to 
examine the effect of PGV-0 and PGV-1 and 
their combination with doxorubicin on cell cycle 
and apoptosis of MCF-7 breast cancer cells. 
 
METHODE 
Cytotoxic Assay (MTT Method) 
The method was modified from Mosmann 
(1983). MCF-7 cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing Fetal Bovine Serum (FBS) 10% (v/v) 
and penicillin-streptomycin 1 % (v/v). Cells 
(5x10
3
 cells/well) were transfered to 96-well 
plate and incubated for 24 hours (70-80% 
confluent). Cells were treated by PGV-0 
(Curcumin Research Center UGM), PGV-1 
(Curcumin Research Center UGM) doxorubicin 
(Ebewe), and their combination, and incubated 
for 24 hour. At the end of the incubation, MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide] 0,5 mg/ml were added to 
each wells and the cells were incubated for 4 
hours in 37 C. Viable cells reacts with MTT to 
form purple formazan crystal. After 4 hours, 
stopper sodium dodesil sulphate 10% in 0,1 N 
HCl solution were added to dissolve formazan 
crystal. Cells were incubated over night and 
protected from light. Cells were shaken for 10 
minutes before read by ELISA reader at  595 
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nm. The absorbance of each well converted to 
percentage of viable cells : 
 
% Viable cells = 
 
 Treated cells abs – Medium control abs  x 100% 
 Cells control abs - Medium control abs 
 
Flowcytometry Assay 
Cells (5x10
5
 cells/well) were transferred 
into 6-well plate and incubated until the cells 
return to normal condition. Cells were treated 
by PGV-0, PGV-1, doxorubicin, and their 
combination, and incubated for 24 hours. At the 
end of the incubation, the media containing free 
cells suspension were taken and transferred 
into 1.5 ml eppendorfs, then it were 
centrifugated (2000 rpm, 3 minutes) and the 
supernatant were removed. The cell in 6-well 
plate were added by PBS, and the PBS were 
transferred into previous eppendorfs. The 
eppendorfs were centrifugated and the 
supernatant were removed again. This steps 
were repeated before the cells harvested by 
trypsin-EDTA 0,025%. Harvested cells were 
transferred into the eppendorfs and 
centrifugated (2000 rpm, 30 seconds). The 
remaining cells in the 6-well plate were rinsed 
with PBS and transferred into the eppendorfs. 
The eppendorfs were centrifugated and the 
supernatant were removed. Pellet cells in 
eppendorfs washed by cold PBS and added by 
propidium iodide (PI) reagents. The eppendorfs 
were wrapped in aluminum foil and incubated in 
37ºC for 10 minutes. After 10 minutes, cell 
suspension were homogenated and transferred 
into the flowcyto-tube to be analyzed by 
flowcytometer. 
 
Result and Discussion 
PGV-0 and PGV-1 have been proved to 
have cytotoxic and antiproliferative effect 
against several cancer cell lines such as T47D, 
HeLa, Raji and Myeloma. In this research, 
single treatment of PGV-0 and PGV-1 showed 
cytotoxic effect on MCF-7 cells with IC50 50 µM 
and 6 µM (Figure 1A and Figure 1B). This result 
showed that the PGV-0 and PGV-1 potential as 
anticancer agent.  
While doxorubicin showed strong 
cytotoxic effect in MCF-7 breast cancer cell 
lines (Figure 1C) with IC50 350 nM. This is due 
to the characteristic of MCF-7 which is resistant 
to doxorubicin by overexpressing anti-apoptotic 
protein Bcl-2 and P-glycoprotein efflux pump 
(Davis et al., 2003). To increase the sensitivity 
of MCF-7 cells towards doxorubicin, we 
combined doxorubicin with PGV-0 and PGV-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
 
Figure 1–The effect of PGV-0 (A), PGV-1 (B) and doxorubicin (C) to the viability of MCF-7 breast cancer cells. The assay 
performed by incubating 5x10
3
 cells/well with PGV-0 (0.5-100µM), PGV-1 (1-25µM) and doxorubicin (100-1100 nM) on 
MCF-7 for 24 hours. After 24 hours, cells were added by MTT reagent to calculate the absorbance which represent viable 
cells. IC50 value were calculated from linier regresion of log concentration vs % viable cell (p<0,05). 
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Synergistic effect of combination 
between PGV-0, PGV-1 and doxorubicin could 
be occured via cell cycle modulation (Table 1 
and Figure 2). Cell cycle analysis of both breast 
cancer cell lines showed that single treatment 
of Doxorubicin 175 nM induced G2/M arrest. 
Single treatment of PGV-0 5 µM induced G1 
arrest, while in higher dose (12.5  µM) PGV-0 
induced apoptosis. Combination of doxorubicin 
175 nM-PGV-0 5 µM induced apoptosis. 
Combination of doxorubicin 175 nM-PGV-0 
12.5 µM also increased apoptosis induction 
compared with control and doxorubicin single 
treatment. These results showed that the 
combination increased apoptosis induction of 
doxorubicin single treatment with dose 
dependent mechanism. The higher dose of 
PGV-0 in combination, the higher of apoptosis 
induction occured.   
 
Table 1–MCF-7 Cell distribution after treatment of PGV-0, PGV-1, doxorubicin, and their combination for 24 hours 
Treatment Concentration 
Sub G1 
(%) 
G1 
(%) 
S 
(%) 
G2/M 
(%) 
Control - 4.00 50.22 17.43 19.73 
Dox 175 nM 8.21 26.08 9.00 52.03 
PGV-0 5 M 8.72 65.25 8.96 12.01 
PGV-0 12.5 M 19.74 27.39 19.50 27.28 
PGV-0+Dox 5 M - 175 nM 25.01 21.87 6.59 37.52 
PGV-0+Dox 12.5 M - 175 nM 44.33 34.15 6.67 11.57 
PGV-1 0.6 M 3.77 60.11 11.20 16.80 
PGV-1 1.5 M 24.58 18.68 12.09 25.92 
PGV-1+Dox 0.6 M - 175 nM 12.62 18.34 5.04 53.14 
PGV-1+Dox 1.5 M - 175 nM 34.13 27.92 6.89 29.07 
 
Single treatment of PGV-1 0.6 µM 
induced G1 arrest while in higher dose (1.5  
µM) PGV-1 induced apoptosis. Combination of 
doxorubicin 175 nM-PGV-1 0.6 µM induced 
apoptosis. Combination of doxorubicin 175 nM 
and PGV-0 1.5 µM also increased apoptosis 
induction than combination in lower dose of 
PGV-1. Single treatment both of PGV-0 and 
PGV-1 in lower dose induced G1 arrest, but in 
the higher dose both of them induced 
apoptosis. These results showed that the 
combination increased apoptosis induction of 
doxorubicin single treatment with dose 
dependent mechanism. The higher dose of 
PGV-1 in combination, the higher of apoptosis 
induction occured.  
MCF-7 cells showed overexpression of 
Bcl-2 and P-glyco Protein (PgP) so that it is 
resistance to apoptosis. Single treatment of 
doxorubicin induced overexpression of PgP in 
MCF-7 cells (Mealey et al., 2002). Transport of 
drug using PgP need ATP to bring the drug 
outsid the cells (Chung et al., 2005), so that 
concentration of chemotherapeutic agent inside 
of cell will decrease and also decrease the 
efficacy of chemotherapeutics. Resistance of 
chemotherapeutics in cancer cells also caused 
by cell cycle arrest, so combination of 
chemotherapeutics with an agent which is 
induce apoptosis directly without cell cycle 
arrest mechanism is better than an agent which 
only acts in cell cycle arrest.  
Single treatment of PGV-0 and PGV-1 in 
lower dose showed G1 arrest. Curcumin 
induced apoptosis via ROS generation 
(Moussavi et al., 2005) so that PGV-0 and 
PGV-1 probably induced apoptosis in the same 
pathway. In the lower dose, curcumin and its 
analogue probably does not enough to induce 
apoptosis and induce G1 arrest, but in the 
higher dose curcumin and its analogue induce 
apoptosis. In the high dose, curcumin 
upregulate p53 expression (Choudhuri et al., 
2005) so that the apoptosis induction will be 
occured
.  
                             
Figure 2–MCF-7 cell cycle analysis after treatment of PGV-0, PGV-1, doxorubicin, and their combination. MCF-7 cell were 
treated by PGV-0, doxorubicin, and their combination for 24 hours and stained by PI reagent before analyzed by 
flowcytometer.  
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Apoptosis could be occured through 
mitochondrial independent pathway via Fas 
receptor by activating caspase 8, or mitochon-
drial dependent pathway via activation p53 to 
transcript pro apoptotic regulator protein (Bad, 
Bax and Bid). MCF-7 cells expressed p53 so 
that apoptosis pathway occured via p53 
pathway. Doxorubicin induces apoptosis 
through intrinsic mechanism via p53 pathway 
which is induce transcription of pro-apoptosis 
protein (Bax) (Minotti et al., 2004). Single 
treatment of doxorubicin 200 nM in MCF-7 cells 
induced expression of Bax (Li et al., 2007). 
Curcumin upregulate Bax in MCF-7/TH cells 
(Ramachandrand and You, 1999). PGV-0 and 
PGV-1 probably upregulate Bax and increased 
apoptosis induction, but it is need to be explore 
details.  
Resistance of cancer cells is regulated by 
NF-κB (Olivier et al., 2006). Doxorubicin 
induced overexpression of PgP via activation of 
NF-κB (Wang et al., 2002). Doxorubicin also 
increase expression of phosporilated Akt kinase 
in MCF-7 cells (Li et al., 2005) which is also 
take a place in activation of NF-κB (Simstein et 
al., 2003). Activation of NF-kB will increase 
expression of Bcl-2 so that cancer cells also 
resistant to apoptosis (Ruddon, 2007). 
Curcumin inhibited activation of NF-κB, 
downregulated Bcl-2 and downregulated Akt 
(Agarwal and Shishoida, 2006). Inhibition of 
NF-κB activation will down regulated PgP and 
Bcl-2, so that apoptosis will occured. 
Combination of PGV-0 and PGV-1 with 
doxorubicin probably inhibit activation of NF-κB, 
down regulated PgP and Bcl-2, but the 
mechanism of combination need to be explored 
further.  
This result showed the potency of PGV-0 
and PGV-1 to be delevoped as co-chemothe-
rapeutic agent for doxorubicin by inducing 
apoptosis and cell cycle arrest. The use of 
doxorubicin together with PGV-0 and PGV-1 is 
expected to increase the activity and reduce the 
side effects of doxorubicin. However, the 
molecular mechanism of apoptotic induction 
and cell cycle arrest by this combination need 
to be explored further.  
 
 
CONCLUSSION 
This research shows that combination of 
PGV-0, PGV-1 and doxorubicin synergically 
increase the effect of doxorubicin through 
apoptotic induction and cell cycle arrest. Based 
on this result, PGV-0 and PGV-1 are potential 
to be delevoped as co-chemotherapeutic agent 
for doxorubicin.  
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